RxDoctor Payments Data

Mikio Tachibana, MD

Internal Medicine · Fountain Valley, CANPI 1598721227

Payments from drug & device makers

$5,510in general payments, 2019–2025

Across 147 payments — averaging $37.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amarin Pharma, Inc.$1K
  • Amgen$801
  • Lilly USA, LLC$418
  • Inari Medical, Inc.$177
  • Boehringer Ingelheim$160
  • plus $739 from 10 others

What the payments were for

  • Food & beverage$5,492100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,510 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$164,409
Medicare patients
224
Services billed
1,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$62,588
GlyxambiEmpagliflozin/Linagliptin37$55,256
FarxigaDapagliflozin Propanediol48$47,060
JardianceEmpagliflozin33$43,476
JanuviaSitagliptin Phosphate21$30,941
ProliaDenosumab18$29,732
XareltoRivaroxaban17$15,460
VascepaIcosapent Ethyl12$7,411
Atorvastatin Calcium585$4,695
Rosuvastatin Calcium240$3,817
Wixela InhubFluticasone Propion/Salmeterol32$3,174
Losartan Potassium344$2,388
Fluticasone Propionate118$2,262
Calcitonin-SalmonCalcitonin,salmon,synthetic27$2,190
SynthroidLevothyroxine Sodium24$2,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimGlyxambi, Jardiance$160$98,73370 claims
AstraZenecaFarxiga$1,973$47,06048 claims
MerckJanuvia$149$30,94121 claims
AmgenProlia$801$29,73218 claims
Johnson & JohnsonXarelto$66$15,46017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fountain Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →